Barclays raised the firm’s price target on Incyte (INCY) to $116 from $115 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte announces CHMP opinion recommending approval of Zynyz combination
- Intel upgraded, Domino’s downgraded: Wall Street’s top analyst calls
- Wells downgrades Incyte to Equal Weight on lack of catalysts
- Incyte downgraded to Equal Weight from Overweight at Wells Fargo
- Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis